Avita Medical
(ASX:AVH) has received a new US FDA approval for its RedCell device to treat burn injuries.
The clinical company, focused on skin regeneration says the FDA supplement approval for its cell harvesting device will allow its device to be used without comparison to a conventional graft.
The supplementary FDA approval also allows patients with 5-50 per cent burns to receive treatment, instead of extensive burns.
The company says the approval also helps with facility enrollments, and allows increased participation at burn centres.
Shares in Avita Medical
(ASX:AVH) closed 7.58 per cent higher yesterday to 7.1 cents.
